Technologies
PDF


WARF: P110346US02

Patch for Delivering Therapeutic Cells into Heart


INVENTORS -

Eric Schmuck, Kurt Saupe

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a new type of epicardial patch for treating damaged heart tissue.
OVERVIEWThroughout a person’s lifetime the heart undergoes slow cellular turnover. This steady regeneration is critical to maintaining healthy cardiac function from birth to old age. The heart’s ability to replenish itself is severely weakened following a heart attack, disease or other injury.

One approach to healing damaged hearts is to introduce potentially therapeutic cells, such as stem cells. Directly injecting cells into a beating, unstable heart is challenging and has been met with mixed success. An alternative method is to preload the cells into an epicardial ‘patch’ that can be affixed to a desired area of the heart. The cells release and migrate into tissue where they facilitate regeneration.

This approach has been investigated using patches made of synthetic materials as well as naturally occurring biomaterials. One problem is that none of these patches are derived from heart-specific cells, which can incite an anti-inflammatory response. Also, they must be glued or sutured to the heart and may fall apart.
THE INVENTIONUW–Madison researchers have developed a new epicardial patch derived from cardiac-specific cells that can adhere to the heart without glue or sutures. The patch may be preloaded with stem cells, skeletal myoblasts or any other potentially therapeutic cell to treat injured or damaged hearts.

The patch is made of isolated three-dimensional cardiac extracellular matrix (ECM). Its composition mimics natural cardiac ECM. Along with other components, it is made up largely of the structural proteins fibronectin, collagen and elastin.
APPLICATIONS
  • Epicardial patch for treating heart disease or injury
KEY BENEFITS
  • New patch is myocardial in origin and composition.
  • Three-dimensional structure is more natural.
  • Affixes readily – no glue or sutures
  • Moves flexibly with the heart
STAGE OF DEVELOPMENTA patch was tested on a mouse model of myocardial infarction, as well as on its ability to release human mesenchymal stromal cells into heart muscle tissue.

The development of this technology was supported by WARF Accelerator. WARF Accelerator selects WARF's most commercially promising technologies and provides expert assistance and funding to enable achievement of commercially significant milestones. WARF believes that these technologies are especially attractive opportunities for licensing.
Contact Information
For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.